Ku ya 22 Gicurasi 2025, Allist Pharmaceuticals yatangaje ko umuti wayo mushya witwa Airuikai (Ibinini bya Glecirasib Citrate), umuti ubuza KRAS-G12C, wemejwe ku mugaragaro kugira ngo utangire ku isoko n'Ikigo cy'Igihugu gishinzwe Ibikoresho by'Ubuvuzi (NMPA). Ukwemeza kwemerera Airuikai gukoreshwa mu kuvura abarwayi bakuru barwaye kanseri y'ibihaha ya KRAS®®G12C (NSCLC) yahinduwe mbere, bakaba barahawe nibura umurongo umwe w'ubuvuzi bw'umubiri. Ibi ni ubundi buryo bushya bwo kuvura kanseri y'ibihaha bwemejwe kuri Allist Pharmaceuticals, butanga uburyo bushya bwo kuvura abarwayi ba kanseri y'ibihaha yahinduwe na KRASG12C (NSCLC) kandi bufasha kuvugurura imiterere y'ubuvuzi bw'iyi kanseri igoye kuvura.
Kwemeza gushingiye ku byavuye mu bushakashatsi bw’ingenzi bwakozwe mu cyiciro cya kabiri cy’uburyo bwo kuvura hakoreshejwe ukuboko kumwe, busuzuma umutekano, ubushobozi bwo kwihanganira no kugira akamaro kwa Glecirasib ku barwayi bafite kanseri y’ibihaha itari iy’uturemangingo duto kandi bafite KRASG12Cmutations bananiwe cyangwa batihanganira ubuvuzi busanzwe.
Ibisubizo byagaragaje ko Goleresai ari ingirakamaro kandi yihanganirwa neza. Ku ya 28 Nzeri 2024, abarwayi 119 ba NSCLC bashyizwe mu isesengura. Igipimo cy’ubutabazi bw’ibanze (cORR), nk’uko byagenzuwe na Komite Yigenga Ishinzwe Isuzuma (IRC), cyari 49.6% (40.2%-59.0%), hamwe n’igipimo cyo kurwanya indwara (DCR) cya 86.3% (78.7%-92.0%). Igihe cy’ubutabazi bw’ibanze (DOR) cyari amezi 14.5 (amezi 9.6 kugeza bitagereranyijwe), igihe cy’ubutabazi bw’ibanze butarimo iterambere (PFS) cyari amezi 8.2 (5.2–11.1), naho igihe cy’ubutabazi bw’ibanze (OS) cyari amezi 17.5 (amezi 13.6 kugeza bitagereranyijwe).
Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.
Nimero ya Terefone: 4008803716
Email：myimmnet@163.com
Igihe cyo kohereza: Gicurasi-27-2025